Derrick Sung Joins Aerin Medical as Chief Financial Officer
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry
Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/
![Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)](https://mms.businesswire.com/media/20231120576987/en/1949074/4/Sung_Derrick.jpg)
Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)
"It is with great pleasure that we welcome Derrick as the latest addition to our leadership team," said Matt Brokaw, CEO of Aerin Medical. "With a proven track record of financial leadership and a wealth of operating expertise, Derrick will play a pivotal role in accelerating our pursuit of a new standard of care for millions of untreated sufferers of ENT conditions."
Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation (NASDAQ:LUNG) where he scaled the finance organization and led the company through significant growth and a successful IPO. Before that, he led strategy and corporate development at iRhythm Technologies (NASDAQ:IRTC). Previously, Sung spent seven years on Wall Street as a senior equity research analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group, and designed heart catheters as an R&D engineer for Guidant Corporation. He received his Ph.D. in bioengineering from the University of California, San Diego, his Master of Business Administration from San Diego State University, and his Bachelor of Science degree in mechanical engineering from Stanford University.
"I am excited to join the exceptional team at Aerin Medical as we embark on the next phase of growth," said Sung. "Fueled by compelling fundamentals and a rare financial profile, we are poised to achieve remarkable success."
About Aerin Medical
Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 100,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120576987/en/